Inferanserin (Ventrus BioSciences) in Phase III for treatment of Haemorrhoids

Ventrus Biosciences Inc. expects to report in June 2012 the results of a pivotal Phase III trial of inferanserin (VEN 309) a highly selective peripheral 5-HT2A receptor antagonist and topical treatment for Haemorrhoids. The Phase III trial is being conducted in 600 patients at 70 centres in the USA and its primary endpoint will be cessation of bleeding by day 7 though day 14 and secondary endpoint will be cessation of itching and pain by day 7 though day 14. A successful Phase IIb study is reported online in Clinical Therapeutics see http://www.sciencedirect.com/science/journal/aip/01492918.and will be published in the print edition in the February issue. If approved inferanserin will be the first FDA approved treatment for haemorrhoids which affects approximately 12.5 million Americans.